Clinical Pharmacology & Biopharmaceutics
黑料网
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 1089
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Pharmaceutical treatment of obesity
3rd Annual Congress on Hospital and Clinical Pharmacy
Sofia Konstantinidou
Athens Medical Group, Greece
ScientificTracks Abstracts: Clin Pharmacol Biopharm
Abstract
Although the treatment of obesity with a healthy dietary intervention can have long-term results, this seems to happen only in a small patient population, mainly due to adaptive changes in appetite regulation mechanisms that ultimately lead to increased food intake. Regarding the pharmaceutical treatment of obesity, various medicinal substances have been tested in recent decades, most of which have been withdrawn from the market due to adverse effects. Indications for administration of anti-obesity drugs are: BMI 芒�?楼30 kg/m2 or BMI 芒�?楼27kg/m2 with comorbidity related to obesity, such as type 2 diabetes mellitus (T2DM), arterial hypertension, fatty infiltration, etc. Currently, three medicinal preparations have official approval in Europe for the treatment of obesity, i.e., orlistat, liraglutide, burpopion/ naltrexone, and several substances are being tested in clinical trials that hopefully soon will enter the market. The purpose of this speech is to describe the pharmaceutical treatment of obesity, current and future perspectives.Biography
Sofia Konstantinidou is the Head of clinical pharmacy department at Athens Medical Centre, Greece. She is also a PhD Candidate in Clinical Pharmacology- Metabolic Syndrome and Obesity, at Athens Medical School of the National and Kapodistrian University of Athens, in ‘Cardiovascular and Metabolic Effects of Obesity Drugs’. She holds an MSc in Clinical Pharmacy, International Policy and Practice from UCL of London and an MPharm degree (1st Class Honours) from King’s College London. She has been an invited speaker in several international scientific conferences and published more than 15 papers in peer-reviewed journals. Moreover, she has been a reviewer in international journals.
